• Vaccine Name: SHR3/DMT
• Target Pathogen: Mycobacterium tuberculosis
• Target Disease: Tuberculosis
• Type: Subunit vaccine
• Status: Research
• Host Species for Licensed Use: Mouse
• Antigen: SHR3 fusion protein, composed of Rv1626, Rv2866 and Rv1884(Zhang et al., 2024).
• Rv1626 gene engineering:
  • Type: Fusion Protein
  • Description: use in preparation of fusion protein(Zhang et al., 2024).
  • Detailed Gene Information: Click Here.
• relG gene engineering:
  • Type: Fusion Protein
  • Description: This is use for preparation of fusion protein(Zhang et al., 2024).
  • Detailed Gene Information: Click Here.
• rpfC gene engineering:
  • Type: Fusion Protein
  • Description: Use in preparation of fusion protein(Zhang et al., 2024).
  • Detailed Gene Information: Click Here.
• Preparation: Recombinant fusion protein expressed in E. coli, purified by Ni-NTA affinity chromatography, dialyzed into phosphate-buffered saline, and formulated with DMT adjuvant as a subunit vaccine(Zhang et al., 2024).
• Immunization Route: subcutaneous injection

Mouse Response

• Host Strain: C57BL/6
• Host age: 6 week old
• Host gender: female
• Vaccination Protocol: Mice were immunized subcutaneously. The BCG+SHR3/DMT group received BCG priming at week 0 followed by two booster doses of SHR3/DMT at 3-week intervals. SHR3/DMT and subunit groups were immunized every 3 weeks over a 9-week period(Zhang et al., 2024).
• Immune Response: Vaccination induced strong antigen-specific Th1-type immune responses characterized by increased IFN-?, TNF-?, and IL-2 secretion from CD4? and CD8? T cells, with low IL-4 levels. The BCG+SHR3/DMT group produced the highest IgG titers and IgG2a/IgG1 ratios (>1), indicating a Th1-dominant response (Zhang et al., 2024).
• Information about this animal model: Mouse Model for TB research